Evidence map›Paper›PMID 29178401›Full record

ArticleCancer science2018

Childhood cancer incidence and survival in Japan and England: A population-based study (1993-2010).

Kayo Nakata, Yuri Ito, Winnie Magadi, Audrey Bonaventure, Charles A Stiller, Kota Katanoda, Tomohiro Matsuda, Isao Miyashiro, Kathy Pritchard-Jones, Bernard Rachet

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kayo NakataCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.ORCID http://orcid.org/0000-0001-9782-8637
Yuri ItoCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.ORCID http://orcid.org/0000-0002-1407-2393
Winnie MagadiCancer Survival Group, London School of Hygiene & Tropical Medicine, London, UK.
Audrey BonaventureCancer Survival Group, London School of Hygiene & Tropical Medicine, London, UK.
Charles A StillerNational Cancer Registration and Analysis Service, Public Health England, Oxford, UK.
Kota KatanodaCenter for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.ORCID http://orcid.org/0000-0001-8687-1269
Tomohiro MatsudaCenter for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
Isao MiyashiroCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Kathy Pritchard-JonesDevelopmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID http://orcid.org/0000-0002-2384-9475
Bernard RachetCancer Survival Group, London School of Hygiene & Tropical Medicine, London, UK.

Funding

Cancer Research UK 11700Cancer Research UK 18525
6 · The paper itself

Abstract

The present study aimed to compare cancer incidence and trends in survival for children diagnosed in Japan and England, using population-based cancer registry data. The analysis was based on 5192 children with cancer (age 0-14 years) from 6 prefectural cancer registries in Japan and 21 295 children diagnosed in England during 1993-2010. Differences in incidence rates between the 2 countries were measured with Poisson regression models. Overall survival was estimated using the Kaplan-Meier method. Incidence rates for Hodgkin lymphoma, renal tumors and Ewing sarcomas in England were more than twice as high as those in Japan. Incidence of germ cell tumors, hepatic tumors, neuroblastoma and acute myeloid leukemia (AML) was higher in Japan than in England. Incidence of all cancers combined decreased in Japan throughout the period 1993 to 2010, which was mainly explained by a decrease in registration of neuroblastoma in infants. For many cancers, 5-year survival improved in both countries. The improvement in survival in chronic myeloid leukemia (CML) was particularly dramatic in both countries. However, 5-year survival remained less than 80% in 2005-2008 in both countries for AML, brain tumors, soft tissue sarcomas, malignant bone tumors and neuroblastoma (age 1-14 years). There were significant differences in incidence of several cancers between countries, suggesting variation in genetic susceptibility and possibly environmental factors. The decrease in incidence for all cancers combined in Japan was related to the cessation of the national screening program for neuroblastoma. The large improvement in survival in CML coincided with the introduction of effective therapy (imatinib).

Indexed as

AdolescentBone NeoplasmsChildChild, PreschoolEnglandHodgkin DiseaseHumansIncidenceInfantInfant, NewbornJapanKidney NeoplasmsNeoplasmsSarcoma, EwingSurvival Analysiscancer registry datachildhood cancerchildhood cancer incidence and survivalepidemiologypopulation-based study

Identifiers

PMID29178401
PMCPMC5797810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.